Summary

Persistence Market Research has recently published a detailed report on the global OTC Pet Medication Market. This report offers an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, providing comprehensive insights into the market structure.

Key Insights:

• OTC Pet Medication Market Size (2024E): USD 9.60 Bn
• Projected Market Value (2033F): USD 14.7 Bn
• Global Market Growth Rate (CAGR 2024 to 2033): 4.8%

OTC Pet Medication Market - Report Scope:

The OTC Pet Medication Market encompasses a broad range of products designed for the treatment and prevention of common health issues in pets. This market includes medications such as flea and tick treatments, heartworm medications, pain relief, and nutritional supplements. It caters to various segments including dogs, cats, and other pets, and is distributed through channels like pet stores, online retailers, and veterinary clinics. Market growth is driven by increasing pet ownership, heightened awareness of pet health, and a preference for convenient and accessible treatment options.

Market Growth Drivers:

Several factors are driving the global OTC Pet Medication Market. Rising pet adoption rates and increased spending on pet healthcare, especially in developed regions, boost the demand for OTC pet medications. Technological advancements in medication formulations and delivery methods improve effectiveness and ease of administration, further expanding the market. Additionally, the trend of pet owners opting for preventive care and over-the-counter treatments for minor health issues fuels the demand for these products. Higher disposable income and a focus on pet wellness also contribute to market growth.

Market Restraints:

Despite promising growth prospects, the OTC Pet Medication Market faces challenges such as the high cost of certain medications and potential side effects like allergic reactions and toxicity. The presence of numerous local and unorganized players offering lower-cost alternatives can limit market share for established brands. Additionally, stringent regulations on pet medications and the need for continuous innovation to meet evolving pet health needs impact the market. Effective pet owner education, competitive pricing, and ongoing investment in research and development are essential to address these issues and maintain a competitive edge.

Market Opportunities:

Significant opportunities exist in the market, driven by the rising trend of preventive pet healthcare and increased awareness of pet wellness. Developing high-quality and easy-to-administer OTC medications meets the growing demand for effective and convenient treatment options. The expansion of e-commerce platforms offers new growth channels, allowing companies to reach a broader audience. Increasing urbanization and the rising number of pet-owning households drive the demand for OTC pet medications. Strategic partnerships, investments in new technologies, and innovative medication formulations are crucial for capitalizing on emerging opportunities and maintaining market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the global OTC Pet Medication Market growth?
• Which types and applications of OTC pet medications are leading adoption in various pet segments?
• How are technological advancements influencing the competitive landscape of the OTC Pet Medication Market?
• Who are the key players in the OTC Pet Medication Market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global OTC Pet Medication Market?

Competitive Intelligence and Business Strategy:

Leading players in the global OTC Pet Medication Market, such as Zoetis Inc., Bayer AG, and Elanco Animal Health, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced medication formulations and delivery methods, such as chewable tablets and topical treatments. Collaborations with veterinary clinics, pet health organizations, and online platforms facilitate market access and promote new product adoption. Emphasis on pet owner education, high-quality products, and comprehensive marketing strategies fosters market growth and enhances brand loyalty in the evolving OTC Pet Medication Market landscape.

Key Companies Profiled:

• Bayer Companion Animal
• Boehringer Ingelheim
• Animal Health
• Ceva Sante Animate
• Merck Inc.
• Zoetis Inc.
• Elanco
• Virbac SA
• Vetoquinol SA
• Frontline
• Zymox
• ChloraSeb
• Sulfox
• Adequan
• Dechra Pharmaceuticals PLC

OTC Pet Medication Market by Product Type:

• Fleas & Ticks
• Pain Relief & Arthritis
• Dewormers
• Others

OTC Pet Medication Market by Pet Type:

• Dogs
• Cats
• Birds
• Fish & Reptiles
• Small Pets
• Others

OTC Pet Medication Market by Medicine Form:

• Chewable & Tablets
• Capsules & Ointment
• Sprays
• Others

OTC Pet Medication Market by Sales Channel:

• Pet Specialty Stores
• Veterinary Clinics
• Drug & Pharmacy Stores
• Online Retail
• Others

OTC Pet Medication Market by Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Overview
1.2. Summary of Key Statistics
1.3. Summary of Key Findings
1.4. Product Evolution Analysis
1.5. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.1.1. World Class R&D driving Unrelenting Innovation
3.1.2. Consumer Trends Shaping the Future
3.1.3. Rising Number of Obese Pets Boosts the Demand for Therapeutic Offerings
3.1.4. Pet Humanization driving Sales of Medicinal Products
3.2. Product Innovation Trends
3.3. Future Prospects of the OTC Pet Medication Industry
3.3.1. Factors Fuelling the Growth
3.3.2. Influx of Brands
3.3.3. Innovative Distribution and Marketing Strategies
4. Global OTC Pet Medication Market Demand Analysis 2019-2023 and Forecast, 2024-2033
4.1. Historical Market Volume (Units) Analysis, 2019-2023
4.2. Current and Future Market Volume (Units) Projections, 2024-2033
4.3. Y-o-Y Growth Trend Analysis
5. Global OTC Pet Medication Market - Pricing Analysis
5.1. Pricing Analysis By Product Type
5.2. Global Average Pricing Analysis Benchmark
6. Global OTC Pet Medication Market Demand (in Value or Medicine Form in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033
6.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
6.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Market Background
7.1. Macro-Economic Factors
7.1.1. GDP Growth Outlook
7.1.2. Consumer Spending Outlook
7.1.3. GDP Growth Rate Analysis
7.1.4. Internet Penetration Rate Outlook
7.1.5. Income Group Population Overview
7.1.6. Per Capita Disposable Income
7.2. Forecast Factors - Relevance & Impact
7.2.1. Top Companies Historical Growth
7.2.2. Urbanization Growth Outlook
7.2.3. Others
7.3. PESTLE Analysis of Global OTC Pet Medication Market
7.4. Investment Feasibility Matrix of OTC Pet Medication Market
7.5. Porter’s Five Forces Analysis of Global OTC Pet Medication Market
7.6. Market Dynamics
7.6.1. Drivers
7.6.2. Restraints
7.6.3. Opportunity Analysis
8. Global OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033, By Product Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Product Type, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product Type, 2024-2033
8.3.1. Fleas & Ticks
8.3.2. Pain Relief & Arthritis
8.3.3. Dewormers
8.3.4. Others
8.4. Market Attractiveness Analysis By Product Type
9. Global OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033, by Pet Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) and Volume Analysis By Pet Type, 2019-2023
9.3. Current and Future Market Size (US$ Bn) and Volume Analysis and Forecast By Pet Type, 2024-2033
9.3.1. Dogs
9.3.2. Cats
9.3.3. Birds
9.3.4. Fish & Reptiles
9.3.5. Small Pets
9.3.6. Others
9.4. Market Attractiveness Analysis By Pet Type
10. Global OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033, by Medicine Form
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) and Volume Analysis By Medicine Form, 2019-2023
10.3. Current and Future Market Size (US$ Bn) and Volume Analysis and Forecast By Medicine Form, 2024-2033
10.3.1. Chewable & Tablets
10.3.2. Capsules & Ointment
10.3.3. Sprays
10.3.4. Others
10.4. Market Attractiveness Analysis By Medicine Form
11. Global OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033, by Sales Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) and Volume Analysis By Sales Channel, 2019-2023
11.3. Current and Future Market Size (US$ Bn) and Volume Analysis and Forecast By Sales Channel, 2024-2033
11.3.1. Pet Specialty Stores
11.3.2. Veterinary Clinics
11.3.3. Drug & Pharmacy Stores
11.3.4. Online Retail
11.3.5. Others
11.4. Market Attractiveness Analysis By Sales Channel
12. Global OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis by Region, 2019-2023
12.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast by Region, 2024-2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis by Region
13. North America OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
13.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
13.4.1. By Country
13.4.1.1. U.S.
13.4.1.2. Canada
13.4.2. By Product Type
13.4.3. By Pet Type
13.4.4. By Medicine Form
13.4.5. Sales Channel
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Product Type
13.5.3. By Pet Type
13.5.4. By Medicine Form
13.5.5. Sales Channel
14. Latin America OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
14.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
14.4.1. By Country
14.4.1.1. Brazil
14.4.1.2. Mexico
14.4.1.3. Rest of Latin America
14.4.2. By Product Type
14.4.3. By Pet Type
14.4.4. By Medicine Form
14.4.5. Sales Channel
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Product Type
14.5.3. By Pet Type
14.5.4. By Medicine Form
14.5.5. Sales Channel
15. Europe OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
15.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. Italy
15.4.1.3. France
15.4.1.4. U.K.
15.4.1.5. Spain
15.4.1.6. Rest of Europe
15.4.2. By Product Type
15.4.3. By Pet Type
15.4.4. By Medicine Form
15.4.5. Sales Channel
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Product Type
15.5.3. By Pet Type
15.5.4. By Medicine Form
15.5.5. Sales Channel
16. South Asia OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
16.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
16.4.1. By Country
16.4.1.1. India
16.4.1.2. Thailand
16.4.1.3. Indonesia
16.4.1.4. Malaysia
16.4.1.5. Rest of South Asia
16.4.2. By Product Type
16.4.3. By Pet Type
16.4.4. By Medicine Form
16.4.5. Sales Channel
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Product Type
16.5.3. By Pet Type
16.5.4. By Medicine Form
16.5.5. Sales Channel
17. East Asia OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
17.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
17.4.1. By Country
17.4.1.1. China
17.4.1.2. Japan
17.4.1.3. South Korea
17.4.2. By Product Type
17.4.3. By Pet Type
17.4.4. By Medicine Form
17.4.5. Sales Channel
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Product Type
17.5.3. By Pet Type
17.5.4. By Medicine Form
17.5.5. Sales Channel
18. Oceania OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
18.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
18.4.1. By Country
18.4.1.1. Australia
18.4.1.2. New Zealand
18.4.2. By Product Type
18.4.3. By Pet Type
18.4.4. By Medicine Form
18.4.5. Sales Channel
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Product Type
18.5.3. By Pet Type
18.5.4. By Medicine Form
18.5.5. Sales Channel
19. Middle East and Africa OTC Pet Medication Market Analysis 2019-2023 and Forecast 2024-2033
19.1. Introduction
19.2. Pricing Analysis
19.3. Historical Market Size (US$ Bn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
19.4. Market Size (US$ Bn) and Volume Forecast By Market Taxonomy, 2024-2033
19.4.1. By Country
19.4.1.1. GCC Countries
19.4.1.2. Northern Africa
19.4.1.3. South Africa
19.4.1.4. Rest of Middle East and Africa
19.4.2. By Product Type
19.4.3. By Pet Type
19.4.4. By Medicine Form
19.4.5. Sales Channel
19.5. Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Product Type
19.5.3. By Pet Type
19.5.4. By Medicine Form
19.5.5. Sales Channel
20. Key Countries’ OTC Pet Medication Market Analysis 2024
20.1. Introduction
20.1.1. Market Value Proportion Analysis, By Key Countries
20.1.2. Global Vs. Country Growth Comparison
20.2. U.S. OTC Pet Medication Market Analysis
20.2.1. By Product Type
20.2.2. By Pet Type
20.2.3. By Medicine Form
20.2.4. Sales Channel
20.3. Canada OTC Pet Medication Market Analysis
20.3.1. By Product Type
20.3.2. By Pet Type
20.3.3. By Medicine Form
20.3.4. Sales Channel
20.4. Mexico OTC Pet Medication Market Analysis
20.4.1. By Product Type
20.4.2. By Pet Type
20.4.3. By Medicine Form
20.4.4. Sales Channel
20.5. Brazil OTC Pet Medication Market Analysis
20.5.1. By Product Type
20.5.2. By Pet Type
20.5.3. By Medicine Form
20.5.4. Sales Channel
20.6. Germany OTC Pet Medication Market Analysis
20.6.1. By Product Type
20.6.2. By Pet Type
20.6.3. By Medicine Form
20.6.4. Sales Channel
20.7. Italy OTC Pet Medication Market Analysis
20.7.1. By Product Type
20.7.2. By Pet Type
20.7.3. By Medicine Form
20.7.4. Sales Channel
20.8. U.K. OTC Pet Medication Market Analysis
20.8.1. By Product Type
20.8.2. By Pet Type
20.8.3. By Medicine Form
20.8.4. Sales Channel
20.9. China OTC Pet Medication Market Analysis
20.9.1. By Product Type
20.9.2. By Pet Type
20.9.3. By Medicine Form
20.9.4. Sales Channel
20.10. Japan OTC Pet Medication Market Analysis
20.10.1. By Product Type
20.10.2. By Pet Type
20.10.3. By Medicine Form
20.10.4. Sales Channel
20.11. S. Korea OTC Pet Medication Market Analysis
20.11.1. By Product Type
20.11.2. By Pet Type
20.11.3. By Medicine Form
20.11.4. Sales Channel
20.12. India OTC Pet Medication Market Analysis
20.12.1. By Product Type
20.12.2. By Pet Type
20.12.3. By Medicine Form
20.12.4. Sales Channel
20.13. Australia and New Zealand OTC Pet Medication Market Analysis
20.13.1. By Product Type
20.13.2. By Pet Type
20.13.3. By Medicine Form
20.13.4. Sales Channel
20.14. South Africa OTC Pet Medication Market Analysis
20.14.1. By Product Type
20.14.2. By Pet Type
20.14.3. By Medicine Form
20.14.4. Sales Channel
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies (OTC Pet Medication)
21.2. Market Concentration
21.3. Market Share Analysis of Top Players
21.4. Market Presence Analysis
21.4.1. By Regional Footprint of Players
21.4.2. Product Footprint by Players
21.4.3. Channel Footprint by Players
22. Competition Analysis
22.1. Competition Dashboard
22.2. Pricing Analysis by Competition
22.3. Competition Benchmarking
22.4. Competition Deep Dive
22.4.1. Bayer Companion Animal
22.4.1.1. Overview
22.4.1.2. Product Portfolio
22.4.1.3. Profitability by Market Segments (Product/Channel/Region)
22.4.1.4. Sales Footprint
22.4.1.5. Strategy Overview
22.4.1.5.1. Marketing Strategy
22.4.1.5.2. Product Strategy
22.4.1.5.3. Channel Strategy
22.4.2. Boehringer Ingelheim
22.4.2.1. Overview
22.4.2.2. Product Portfolio
22.4.2.3. Profitability by Market Segments (Product/Channel/Region)
22.4.2.4. Sales Footprint
22.4.2.5. Strategy Overview
22.4.2.5.1. Marketing Strategy
22.4.2.5.2. Product Strategy
22.4.2.5.3. Channel Strategy
22.4.3. Animal Health
22.4.3.1. Overview
22.4.3.2. Product Portfolio
22.4.3.3. Profitability by Market Segments (Product/Channel/Region)
22.4.3.4. Sales Footprint
22.4.3.5. Strategy Overview
22.4.3.5.1. Marketing Strategy
22.4.3.5.2. Product Strategy
22.4.3.5.3. Channel Strategy
22.4.4. Ceva Sante Animate
22.4.4.1. Overview
22.4.4.2. Product Portfolio
22.4.4.3. Profitability by Market Segments (Product/Channel/Region)
22.4.4.4. Sales Footprint
22.4.4.5. Strategy Overview
22.4.4.5.1. Marketing Strategy
22.4.4.5.2. Product Strategy
22.4.4.5.3. Channel Strategy
22.4.5. Merck Inc.
22.4.5.1. Overview
22.4.5.2. Product Portfolio
22.4.5.3. Profitability by Market Segments (Product/Channel/Region)
22.4.5.4. Sales Footprint
22.4.5.5. Strategy Overview
22.4.5.5.1. Marketing Strategy
22.4.5.5.2. Product Strategy
22.4.5.5.3. Channel Strategy
22.4.6. Zoetis Inc.
22.4.6.1. Overview
22.4.6.2. Product Portfolio
22.4.6.3. Profitability by Market Segments (Product/Channel/Region)
22.4.6.4. Sales Footprint
22.4.6.5. Strategy Overview
22.4.6.5.1. Marketing Strategy
22.4.6.5.2. Product Strategy
22.4.6.5.3. Channel Strategy
22.4.7. Elanco
22.4.7.1. Overview
22.4.7.2. Product Portfolio
22.4.7.3. Profitability by Market Segments (Product/Channel/Region)
22.4.7.4. Sales Footprint
22.4.7.5. Strategy Overview
22.4.7.5.1. Marketing Strategy
22.4.7.5.2. Product Strategy
22.4.7.5.3. Channel Strategy
22.4.8. Virbac SA
22.4.8.1. Overview
22.4.8.2. Product Portfolio
22.4.8.3. Profitability by Market Segments (Product/Channel/Region)
22.4.8.4. Sales Footprint
22.4.8.5. Strategy Overview
22.4.8.5.1. Marketing Strategy
22.4.8.5.2. Product Strategy
22.4.8.5.3. Channel Strategy
22.4.9. Vetoquinol SA
22.4.9.1. Overview
22.4.9.2. Product Portfolio
22.4.9.3. Profitability by Market Segments (Product/Channel/Region)
22.4.9.4. Sales Footprint
22.4.9.5. Strategy Overview
22.4.9.5.1. Marketing Strategy
22.4.9.5.2. Product Strategy
22.4.9.5.3. Channel Strategy
22.4.10. Frontline
22.4.10.1. Overview
22.4.10.2. Product Portfolio
22.4.10.3. Profitability by Market Segments (Product/Channel/Region)
22.4.10.4. Sales Footprint
22.4.10.5. Strategy Overview
22.4.10.5.1. Marketing Strategy
22.4.10.5.2. Product Strategy
22.4.10.5.3. Channel Strategy
22.4.11. Zymox
22.4.11.1. Overview
22.4.11.2. Product Portfolio
22.4.11.3. Profitability by Market Segments (Product/Channel/Region)
22.4.11.4. Sales Footprint
22.4.11.5. Strategy Overview
22.4.11.5.1. Marketing Strategy
22.4.11.5.2. Product Strategy
22.4.11.5.3. Channel Strategy
22.4.12. ChloraSeb
22.4.12.1. Overview
22.4.12.2. Product Portfolio
22.4.12.3. Profitability by Market Segments (Product/Channel/Region)
22.4.12.4. Sales Footprint
22.4.12.5. Strategy Overview
22.4.12.5.1. Marketing Strategy
22.4.12.5.2. Product Strategy
22.4.12.5.3. Channel Strategy
22.4.13. Sulfox
22.4.13.1. Overview
22.4.13.2. Product Portfolio
22.4.13.3. Profitability by Market Segments (Product/Channel/Region)
22.4.13.4. Sales Footprint
22.4.13.5. Strategy Overview
22.4.13.5.1. Marketing Strategy
22.4.13.5.2. Product Strategy
22.4.13.5.3. Channel Strategy
22.4.14. Adequan
22.4.14.1. Overview
22.4.14.2. Product Portfolio
22.4.14.3. Profitability by Market Segments (Product/Channel/Region)
22.4.14.4. Sales Footprint
22.4.14.5. Strategy Overview
22.4.14.5.1. Marketing Strategy
22.4.14.5.2. Product Strategy
22.4.14.5.3. Channel Strategy
22.4.15. Dechra Pharmaceuticals PLC
22.4.15.1. Overview
22.4.15.2. Product Portfolio
22.4.15.3. Profitability by Market Segments (Product/Channel/Region)
22.4.15.4. Sales Footprint
22.4.15.5. Strategy Overview
22.4.15.5.1. Marketing Strategy
22.4.15.5.2. Product Strategy
22.4.15.5.3. Channel Strategy
22.4.16. Nutramax Laboratories, Inc.
22.4.16.1. Overview
22.4.16.2. Product Portfolio
22.4.16.3. Profitability by Market Segments (Product/Channel/Region)
22.4.16.4. Sales Footprint
22.4.16.5. Strategy Overview
22.4.16.5.1. Marketing Strategy
22.4.16.5.2. Product Strategy
22.4.16.5.3. Channel Strategy
22.4.17. Other Players (As Requested)
22.4.17.1. Overview
22.4.17.2. Product Portfolio
22.4.17.3. Profitability by Market Segments (Product/Channel/Region)
22.4.17.4. Sales Footprint
22.4.17.5. Strategy Overview
22.4.17.5.1. Marketing Strategy
22.4.17.5.2. Product Strategy
22.4.17.5.3. Channel Strategy
23. Assumptions and Acronyms Used
24. Research Methodology